China A-share pharma Q3 results: 129 firms report, innovation drug overseas licensing pays off

The standout here is the shift from headline licensing announcements to actual revenue recognition — a milestone that separates companies with executed overseas deals from those still relying on domestic pricing pressure. The 40%-plus profit-growth cohort is likely concentrated among firms with completed out-licensing, which means the sector's earnings dispersion may widen rather than narrow. Whether that licensing income proves recurring or lumpy is the open question, since concentrated milestone payments can flatter a single quarter. The pace of new deals signed now will determine if this becomes a durable earnings stream.